[Clinical aspects of pelvic histangiopathies. New therapeutic possibilities with danazol]
Review
OA: closed
CC0
AI-generated summary
Danazol treatment at 200-400 mg daily alleviates symptoms of pelvic histangiopathies, including menometrorrhagia and pelvic pain associated with utero-adnexal venous insufficiency, potentially avoiding destructive surgery.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Menometrorrhagia and hypermenorrhoea are often present in patients who also suffer from a state of insufficiency of the utero-adnexal venous system interpretable as a clinical entity of system pathology and accompanied by pictures of acquired venous ectasis. The lack of any easy clinical characteristic objectivisation often prevents easy recognition and complex diagnostic investigation is therefore indispensable. Treatment is often destructive surgery following the failure of the various medical or conservative surgical therapies that are tried. Personal experience in cases in which the clinical picture (big uterus, menometrorrhagia, pelvic pain) presents a pathology of the venous vascular system, can report considerable benefit first and disappearance later of the symptomatology, with treatment using danazol at a dose of 200-300-400 mg/die. This makes demolition surgery, which is not often well accepted by the patient, inopportune.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-05-10T11:16:35.852252+00:00
- pubmed
- last seen: 2026-10-08T21:06:31.728877+00:00
License: CC0
· commercial use OK